NAV

Entospletinib

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Generic Name
Entospletinib
DrugBank Accession Number
DB12121
Background

Entospletinib has been used in trials studying the treatment of Oncology, Follicular Lymphoma, B-cell Malignancies, Mantle Cell Lymphoma, and Non-Hodgkin Lymphoma, among others.

Type
Small Molecule
Groups
Investigational
Structure
3D
Similar Structures
Weight
Average: 411.4591
Monoisotopic: 411.180758329
Chemical Formula
C23H21N7O
Synonyms
  • Entospletinib
External IDs
  • GS 9973
  • GS-9973
  • GS9973

Pharmacology

Indication

Not Available

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UTyrosine-protein kinase SYK
inhibitor
Humans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Not Available
Food Interactions
Not Available

Categories

Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Phenylmorpholines
Alternative Parents
Indazoles / Imidazopyrazines / Dialkylarylamines / Aniline and substituted anilines / Aminopyrazines / N-substituted imidazoles / Imidolactams / Pyrazoles / Heteroaromatic compounds / Oxacyclic compounds
show 3 more
Substituents
Amine / Aminopyrazine / Aniline or substituted anilines / Aromatic heteropolycyclic compound / Azacycle / Azole / Benzenoid / Benzopyrazole / Dialkyl ether / Dialkylarylamine
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
6I3O3W6O3B
CAS number
1229208-44-9
InChI Key
XSMSNFMDVXXHGJ-UHFFFAOYSA-N
InChI
InChI=1S/C23H21N7O/c1-2-17-14-25-28-20(17)13-16(1)21-15-30-8-7-24-23(30)22(27-21)26-18-3-5-19(6-4-18)29-9-11-31-12-10-29/h1-8,13-15H,9-12H2,(H,25,28)(H,26,27)
IUPAC Name
6-(1H-indazol-6-yl)-N-[4-(morpholin-4-yl)phenyl]imidazo[1,2-a]pyrazin-8-amine
SMILES
C1CN(CCO1)C1=CC=C(NC2=NC(=CN3C=CN=C23)C2=CC3=C(C=NN3)C=C2)C=C1

References

General References
Not Available
PubChem Compound
59473233
PubChem Substance
347828420
ChemSpider
31042596
BindingDB
50015448
ChEMBL
CHEMBL3265032
ZINC
ZINC000098208742
PDBe Ligand
CG9
Wikipedia
Syk
PDB Entries
4puz

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
3TerminatedTreatmentNucleophosmin 1-mutated Acute Myeloid Leukemia1
2CompletedTreatmentChronic Lymphocytic Leukemia1
2TerminatedTreatmentChronic Graft-Versus-Host Disease1
2TerminatedTreatmentChronic Lymphocytic Leukemia / Diffuse Large B-Cell Lymphoma (DLBCL) / Follicular Lymphoma ( FL) / Mantle Cell Lymphoma (MCL) / Non-FL Indolent Non-Hodgkin's Lymphoma1
2TerminatedTreatmentChronic Lymphocytic Leukemia / Diffuse Large B-Cell Lymphoma (DLBCL) / Indolent Non Hodgkin's Lymphoma (iNHL) / Mantle Cell Lymphoma (MCL)1
1Active Not RecruitingTreatmentB-cell Malignancy1
1CompletedTreatmentOncology1
1TerminatedTreatmentAcute Myeloid Leukemia / Hematological Malignancy1
1, 2CompletedTreatmentAnemia / B-Cell Prolymphocytic Leukemia / B-cell Small Lymphocytic Lymphoma Recurrent / Chronic Lymphocytic Leukemia (CLL) - Refractory / Follicular Lymphoma Grade IIIa / Grade 1 Follicular Lymphoma / Grade 2 Follicular Lymphoma / Hairy Cell Leukemia (HCL) / Mantle Cell Lymphoma (MCL) / Marginal Zone Lymphoma (MZL) / Recurrent Chronic Lymphocytic Leukemia / Refractory Small Lymphocytic Lymphoma / Richter's Syndrome / Waldenström's Macroglobulinemia (WM)1
1, 2RecruitingTreatmentPreviously Untreated Acute Myeloid Leukemia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP2.82Chemaxon
pKa (Strongest Acidic)11.74Chemaxon
pKa (Strongest Basic)3.74Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count6Chemaxon
Hydrogen Donor Count2Chemaxon
Polar Surface Area83.37 Å2Chemaxon
Rotatable Bond Count4Chemaxon
Refractivity120.86 m3·mol-1Chemaxon
Polarizability44.44 Å3Chemaxon
Number of Rings6Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details1. Tyrosine-protein kinase SYK
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Receptor signaling protein tyrosine kinase activity
Specific Function
Non-receptor tyrosine kinase which mediates signal transduction downstream of a variety of transmembrane receptors including classical immunoreceptors like the B-cell receptor (BCR). Regulates seve...
Gene Name
SYK
Uniprot ID
P43405
Uniprot Name
Tyrosine-protein kinase SYK
Molecular Weight
72065.76 Da
References
  1. Zheng TJ, Lofurno ER, Melrose AR, Lakshmanan HHS, Pang J, Phillips KG, Fallon ME, Kohs TCL, Ngo ATP, Shatzel JJ, Hinds MT, McCarty OJT, Aslan JE: Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function. Am J Physiol Cell Physiol. 2021 May 1;320(5):C902-C915. doi: 10.1152/ajpcell.00296.2020. Epub 2021 Mar 10. [Article]

Drug created at October 20, 2016 21:23 / Updated at May 05, 2022 18:10